Slingshot members are tracking this event:

Gilead (GILD) Presents Data from Open-Label Proof-of-Concept Study Evaluating GS-0976 in Non-Alcoholic Steatohepatitis (NASH)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 21, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Open-label, Proof-of-concept, Gs-0976, Advanced Non-alcoholic Steatohepatitis, Nash